Details of the Drug

General Information of Drug (ID: DMBDAZV)

Drug Name
Amlodipine
Synonyms
Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1], [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 408.9
Topological Polar Surface Area (xlogp) 3
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 8.8-45.8 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3.5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 30% [3]
Clearance
The total body clearance of drug is 7 +/- 1.3 mL/min/kg [5]
Elimination
10% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 30C50 hours [3]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3494 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.005% [8]
Vd
The volume of distribution (Vd) of drug is 21 L/kg [5]
Chemical Identifiers
Formula
C20H25ClN2O5
IUPAC Name
3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES
CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
InChI
InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
InChIKey
HTIQEAQVCYTUBX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2162
ChEBI ID
CHEBI:2668
CAS Number
88150-42-9
DrugBank ID
DB00381
TTD ID
D08JIV
VARIDT ID
DR00563
INTEDE ID
DR0099
ACDINA ID
D00033

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) TTFK1JQ CA2D1_HUMAN Blocker [9], [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertension
ICD Disease Classification BA00-BA04
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DTT CACNA2D1 9.36E-01 -0.03 -0.13
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DTT CACNA2D1 2.81E-05 -0.15 -0.68
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.13E-01 4.03E-02 2.50E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 8.21E-02 8.17E-02 4.35E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amlodipine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Acebutolol DM0TI4U Moderate Increased risk of cardiac depression by the combination of Amlodipine and Acebutolol. Hypertension [BA00-BA04] [30]
Bisoprolol DM3UZ95 Moderate Increased risk of cardiac depression by the combination of Amlodipine and Bisoprolol. Hypertension [BA00-BA04] [30]
Penbutolol DM4ES8F Moderate Increased risk of cardiac depression by the combination of Amlodipine and Penbutolol. Hypertension [BA00-BA04] [30]
Verapamil DMA7PEW Moderate Decreased metabolism of Amlodipine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [31]
Pindolol DMD2NV7 Moderate Increased risk of cardiac depression by the combination of Amlodipine and Pindolol. Hypertension [BA00-BA04] [30]
Labetalol DMK8U72 Moderate Increased risk of cardiac depression by the combination of Amlodipine and Labetalol. Hypertension [BA00-BA04] [30]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Amlodipine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Amlodipine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [32]
Midostaurin DMI6E0R Moderate Decreased metabolism of Amlodipine caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [33]
Arn-509 DMT81LZ Major Increased metabolism of Amlodipine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [34]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Amlodipine caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [35]
Magnesium Sulfate DMVEK07 Moderate Additive hypotensive effects by the combination of Amlodipine and Magnesium Sulfate. Acute pain [MG31] [36]
Emapalumab DMZG5WL Moderate Altered metabolism of Amlodipine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [35]
Mitotane DMU1GX0 Major Increased metabolism of Amlodipine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [34]
Siltuximab DMGEATB Moderate Altered metabolism of Amlodipine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [35]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Amlodipine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [37]
Promazine DMZAL7W Moderate Additive hypotensive effects by the combination of Amlodipine and Promazine. Appearance/behaviour symptom [MB23] [38]
Cilostazol DMZMSCT Moderate Decreased metabolism of Amlodipine caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [39]
Voriconazole DMAOL2S Moderate Decreased metabolism of Amlodipine caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [40]
Posaconazole DMUL5EW Moderate Decreased metabolism of Amlodipine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [40]
Zileuton DMVRIC2 Minor Decreased metabolism of Amlodipine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [41]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Amlodipine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Amlodipine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Amlodipine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Amlodipine caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Amlodipine and Linezolid. Bacterial infection [1A00-1C4Z] [42]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Amlodipine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Amlodipine and Cariprazine. Bipolar disorder [6A60] [38]
Erdafitinib DMI782S Moderate Increased metabolism of Amlodipine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [43]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Amlodipine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Tucatinib DMBESUA Moderate Decreased metabolism of Amlodipine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Bosutinib DMTI8YE Moderate Decreased metabolism of Amlodipine caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [35]
Sotalol DML60TN Moderate Increased risk of cardiac depression by the combination of Amlodipine and Sotalol. Cardiac arrhythmia [BC9Z] [30]
Atorvastatin DMF28YC Moderate Decreased metabolism of Amlodipine caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [45]
Secobarbital DM14RF5 Moderate Increased metabolism of Amlodipine caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [37]
PF-04449913 DMSB068 Moderate Decreased metabolism of Amlodipine caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [46]
Thiopental DMGP8AX Moderate Increased metabolism of Amlodipine caused by Thiopental mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [37]
Mifepristone DMGZQEF Moderate Decreased metabolism of Amlodipine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [47]
Pasireotide DMHM7JS Moderate Increased risk of bradycardia by the combination of Amlodipine and Pasireotide. Cushing syndrome [5A70] [31]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Amlodipine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [35]
Lumacaftor DMCLWDJ Major Increased metabolism of Amlodipine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [34]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Amlodipine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [48]
MK-8228 DMOB58Q Moderate Decreased metabolism of Amlodipine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [31]
Aprepitant DM053KT Moderate Decreased metabolism of Amlodipine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [31]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Amlodipine caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [31]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Amlodipine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [31]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Amlodipine and Selegiline. Depression [6A70-6A7Z] [42]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Amlodipine and Isocarboxazid. Depression [6A70-6A7Z] [42]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Amlodipine and Tranylcypromine. Depression [6A70-6A7Z] [42]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Amlodipine and OPC-34712. Depression [6A70-6A7Z] [38]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Amlodipine and Phenelzine. Depression [6A70-6A7Z] [42]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Amlodipine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [49]
Primidone DM0WX6I Major Increased metabolism of Amlodipine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Amlodipine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [50]
Mephenytoin DM5UGDK Moderate Increased metabolism of Amlodipine caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Cenobamate DMGOVHA Moderate Increased metabolism of Amlodipine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [52]
Stiripentol DMMSDOY Moderate Decreased metabolism of Amlodipine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Fosphenytoin DMOX3LB Major Increased metabolism of Amlodipine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Rufinamide DMWE60C Moderate Increased metabolism of Amlodipine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Ethotoin DMXWOCP Moderate Increased metabolism of Amlodipine caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Phenobarbital DMXZOCG Major Increased metabolism of Amlodipine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Carbamazepine DMZOLBI Major Increased metabolism of Amlodipine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [53]
Nadolol DMW6GVL Moderate Increased risk of cardiac depression by the combination of Amlodipine and Nadolol. Essential hypertension [BA00] [30]
Dantrolene DM1D8XY Moderate Increased risk of hyperkalemia by the combination of Amlodipine and Dantrolene. Fever [MG26] [47]
Tazemetostat DMWP1BH Moderate Increased metabolism of Amlodipine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [54]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Amlodipine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [55]
Miconazole DMPMYE8 Moderate Decreased metabolism of Amlodipine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [40]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Amlodipine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [40]
Ripretinib DM958QB Moderate Decreased metabolism of Amlodipine caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [47]
Avapritinib DMK2GZX Moderate Decreased metabolism of Amlodipine caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [35]
Carteolol DMFMDOB Moderate Increased risk of cardiac depression by the combination of Amlodipine and Carteolol. Glaucoma [9C61] [30]
Metipranolol DMJMVKI Moderate Increased risk of cardiac depression by the combination of Amlodipine and Metipranolol. Glaucoma [9C61] [56]
Levobetaxolol DMSREPX Moderate Increased risk of cardiac depression by the combination of Amlodipine and Levobetaxolol. Glaucoma [9C61] [56]
Levobunolol DMTNFCQ Moderate Increased risk of cardiac depression by the combination of Amlodipine and Levobunolol. Glaucoma [9C61] [56]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Amlodipine caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [57]
Carvedilol DMHTEAO Moderate Increased risk of cardiac depression by the combination of Amlodipine and Carvedilol. Heart failure [BD10-BD1Z] [30]
Boceprevir DMBSHMF Moderate Decreased metabolism of Amlodipine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [58]
Simeprevir DMLUA9D Moderate Decreased metabolism of Amlodipine caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [59]
Telaprevir DMMRV29 Moderate Decreased metabolism of Amlodipine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [58]
Rifampin DMA8J1G Major Increased metabolism of Amlodipine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Rifapentine DMCHV4I Major Increased metabolism of Amlodipine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Amlodipine and Procarbazine. Hodgkin lymphoma [2B30] [42]
MK-1439 DM215WE Minor Decreased metabolism of Amlodipine caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Delavirdine DM3NF5G Moderate Decreased metabolism of Amlodipine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Amlodipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Amlodipine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Efavirenz DMC0GSJ Moderate Increased metabolism of Amlodipine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [62]
Saquinavir DMG814N Moderate Decreased metabolism of Amlodipine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Etravirine DMGV8QU Moderate Increased metabolism of Amlodipine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Amlodipine caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [47]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Amlodipine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Darunavir DMN3GCH Moderate Decreased metabolism of Amlodipine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Atazanavir DMSYRBX Moderate Decreased metabolism of Amlodipine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Ritonavir DMU764S Moderate Decreased metabolism of Amlodipine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Simvastatin DM30SGU Major Decreased metabolism of Amlodipine caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [65]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Amlodipine caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [66]
Cerivastatin DMXCM7H Moderate Decreased metabolism of Amlodipine caused by Cerivastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [45]
Conivaptan DM1V329 Moderate Decreased metabolism of Amlodipine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [67]
Lesinurad DMUR64T Moderate Increased metabolism of Amlodipine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [68]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Amlodipine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [31]
Amobarbital DM0GQ8N Moderate Increased metabolism of Amlodipine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Amlodipine and Propiomazine. Insomnia [7A00-7A0Z] [38]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Amlodipine caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [69]
Pemigatinib DM819JF Moderate Decreased metabolism of Amlodipine caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [35]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Amlodipine and Porfimer Sodium. Lung cancer [2C25] [70]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Amlodipine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [71]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Amlodipine caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [72]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Amlodipine caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [73]
Selpercatinib DMZR15V Moderate Decreased metabolism of Amlodipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
Idelalisib DM602WT Moderate Decreased metabolism of Amlodipine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [31]
IPI-145 DMWA24P Moderate Decreased metabolism of Amlodipine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [31]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Amlodipine caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [74]
Selumetinib DMC7W6R Moderate Decreased metabolism of Amlodipine caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [75]
LGX818 DMNQXV8 Moderate Increased metabolism of Amlodipine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [76]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Amlodipine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [35]
Ubrogepant DM749I3 Moderate Decreased metabolism of Amlodipine caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [77]
Propranolol DM79NTF Moderate Increased risk of cardiac depression by the combination of Amlodipine and Propranolol. Migraine [8A80] [30]
Exjade DMHPRWG Moderate Decreased metabolism of Amlodipine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [78]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Amlodipine and Thalidomide. Multiple myeloma [2A83] [47]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Amlodipine and Siponimod. Multiple sclerosis [8A40] [47]
Fingolimod DM5JVAN Moderate Increased risk of atrioventricular block by the combination of Amlodipine and Fingolimod. Multiple sclerosis [8A40] [79]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Amlodipine and Ozanimod. Multiple sclerosis [8A40] [80]
Rifabutin DM1YBHK Major Increased metabolism of Amlodipine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [34]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Amlodipine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Nilotinib DM7HXWT Moderate Decreased metabolism of Amlodipine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [81]
Imatinib DM7RJXL Moderate Decreased metabolism of Amlodipine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Modafinil DMYILBE Minor Increased metabolism of Amlodipine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [82]
Prochlorperazine DM53SRA Moderate Additive hypotensive effects by the combination of Amlodipine and Prochlorperazine. Nausea/vomiting [MD90] [38]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Amlodipine and Promethazine. Nausea/vomiting [MD90] [38]
Netupitant DMEKAYI Moderate Decreased metabolism of Amlodipine caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [31]
Entrectinib DMMPTLH Moderate Decreased metabolism of Amlodipine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [83]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Amlodipine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [84]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Amlodipine and Safinamide. Parkinsonism [8A00] [42]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Amlodipine and Rasagiline. Parkinsonism [8A00] [42]
Abametapir DM2RX0I Moderate Decreased metabolism of Amlodipine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [85]
Lefamulin DME6G97 Moderate Decreased metabolism of Amlodipine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [86]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Amlodipine caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [87]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Amlodipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [88]
Enzalutamide DMGL19D Major Increased metabolism of Amlodipine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [34]
Darolutamide DMV7YFT Minor Decreased metabolism of Amlodipine caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [89]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Amlodipine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [35]
Ixekizumab DMXW92T Moderate Altered metabolism of Amlodipine due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [35]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Amlodipine and Levomepromazine. Psychotic disorder [6A20-6A25] [38]
Triflupromazine DMKFQJP Moderate Additive hypotensive effects by the combination of Amlodipine and Triflupromazine. Psychotic disorder [6A20-6A25] [38]
Bosentan DMIOGBU Moderate Increased metabolism of Amlodipine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [90]
Everolimus DM8X2EH Moderate Decreased metabolism of Amlodipine caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [47]
Axitinib DMGVH6N Moderate Decreased metabolism of Amlodipine caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [35]
Temsirolimus DMS104F Moderate Decreased metabolism of Amlodipine caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [47]
Tocilizumab DM7J6OR Moderate Altered metabolism of Amlodipine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [35]
Canakinumab DM8HLO5 Moderate Altered metabolism of Amlodipine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [35]
Rilonacept DMGLUQS Moderate Altered metabolism of Amlodipine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [35]
Golimumab DMHZV7X Moderate Altered metabolism of Amlodipine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [35]
Sarilumab DMOGNXY Moderate Altered metabolism of Amlodipine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [35]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Amlodipine and Quetiapine. Schizophrenia [6A20] [38]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Amlodipine and Mesoridazine. Schizophrenia [6A20] [38]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Amlodipine and Thioridazine. Schizophrenia [6A20] [38]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Amlodipine and Aripiprazole. Schizophrenia [6A20] [38]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Amlodipine and Iloperidone. Schizophrenia [6A20] [38]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Amlodipine and Paliperidone. Schizophrenia [6A20] [38]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Amlodipine and Loxapine. Schizophrenia [6A20] [38]
Haloperidol DM96SE0 Moderate Additive hypotensive effects by the combination of Amlodipine and Haloperidol. Schizophrenia [6A20] [38]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Amlodipine and Perphenazine. Schizophrenia [6A20] [38]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Amlodipine and Molindone. Schizophrenia [6A20] [38]
Chlorpromazine DMBGZI3 Moderate Additive hypotensive effects by the combination of Amlodipine and Chlorpromazine. Schizophrenia [6A20] [38]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Amlodipine and Thiothixene. Schizophrenia [6A20] [38]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Amlodipine and Trifluoperazine. Schizophrenia [6A20] [38]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Amlodipine and Risperidone. Schizophrenia [6A20] [38]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Amlodipine and Amisulpride. Schizophrenia [6A20] [38]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Amlodipine and Asenapine. Schizophrenia [6A20] [38]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Amlodipine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [31]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Amlodipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [35]
Larotrectinib DM26CQR Moderate Decreased metabolism of Amlodipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
Armodafinil DMGB035 Minor Increased metabolism of Amlodipine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [82]
LEE011 DMMX75K Moderate Decreased metabolism of Amlodipine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Amlodipine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [91]
Apixaban DM89JLN Moderate Decreased metabolism of Amlodipine caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [35]
Sirolimus DMGW1ID Moderate Decreased metabolism of Amlodipine caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [47]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Amlodipine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [38]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Amlodipine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [92]
⏷ Show the Full List of 172 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Butylated hydroxytoluene E00336 31404 Antioxidant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Calcium phosphate E00298 24456 Anticaking agent; Buffering agent; Desiccant; Diluent
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Trihydroxystearin E00317 25100 Emollient; Emulsifying agent; Solvent; Surfactant; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Amlodipine 10 mg tablet 10 mg Oral Tablet Oral
Amlodipine 2.5 mg tablet 2.5 mg Oral Tablet Oral
Amlodipine 5 mg tablet 5 mg Oral Tablet Oral
Amlodipine Besylate eq 2.5mg base capsule eq 2.5mg base Capsule Oral
Amlodipine Besylate eq 10mg base tablet eq 10mg base Tablet Oral
Amlodipine Besylate eq 5mg base tablet eq 5mg base Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6981).
2 Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. Curr Med Res Opin. 2009 Jan;25(1):177-85.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Meredith PA, Elliott HL: Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992 Jan;22(1):22-31. doi: 10.2165/00003088-199222010-00003.
6 Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K: Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94.
10 Benidipine, an anti-hypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loa... Eur J Pharmacol. 2008 Feb 2;580(1-2):201-13.
11 Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24.
22 Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80.
23 Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7.
24 Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76.
25 Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61.
26 Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9.
27 Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
28 Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).
29 Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
30 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
31 Canadian Pharmacists Association.
32 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
33 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
34 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
35 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36 Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
37 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
38 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
39 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
40 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
41 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
42 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
43 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
44 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
45 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
46 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
47 Cerner Multum, Inc. "Australian Product Information.".
48 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
49 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
50 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
51 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
52 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
53 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
54 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
55 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
56 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
57 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
58 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
59 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
60 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
61 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
62 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
63 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
64 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
65 Product Information. Zocor (simvastatin). Merck & Co, Inc, West Point, PA.
66 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
67 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
68 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
69 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
70 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
71 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
72 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
74 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
75 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
76 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
77 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
78 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
79 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
80 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
81 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
82 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
83 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
84 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
85 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
86 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
87 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
88 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
89 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
90 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
91 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
92 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.